Portfolio Analysis


SV Health Managers LLP was appointed Investment Manager of the Company on 1 January 2005 and Alternative Investment Fund Managers (‘AIFM’) on 21 July 2014. SV Health Managers LLP provides life sciences focused Investment Management services to publicly listed investment funds and venture capital funds.

As at 31 May 2020


IBT Portfolio NAV (m)£297
Number of Portfolio Companies72
Quoted Investments60
Unquoted Investments12

Investment Manager Comment

In May 2020, the Trust’s NAV per share returned 11.8% (GBP) while the NASDAQ Biotechnology Index (NBI) returned 10.9% (GBP). The FTSE All-Share Index returned 3.4% (GBP) and the S&P 500 Index returned 7.0% (GBP). IBT’s share price returned 12.8% (GBP).

The main positive contributors to the NAV in the month were Horizon Therapeutics, Myokardia and Neurocrine. Horizon announced strong sales for its treatment for Thyroid Eye Disease, Tepezza, during their first quarterly update. Myokardia reported positive phase 3 results for their cardiovascular drug Mavacamten. Neurocrine shares were strong as investors realised that COVID-19 impact might be minimal for the company.

The main detractor from the NAV in the month was Gilead, as all other companies posted a positive return in the month. Gilead shares have been relatively volatile throughout the COVID-19 pandemic. The company’s shares initially increased due to the announcement that their COVID-19 drug, Remdesivir, showed positive results in reducing the time patients with the disease spent in hospital. The share price has subsequently decreased, negatively impacting the NAV in the month.


 (NAV, Share Price Change, 5 years)

Source: Bloomberg, mid-price (share price), quoted in sterling and SV Health Managers LLP.
Past performance is not a guide to future performance.
Note: All performance data are quoted net of all costs to the Company.

Top Ten Investments by NAV %





  • You are seeing this because you are accessing IBT’s website for the first time.


  • The information on this website may only be suitable for certain types of investors and is not intended to be used or relied upon by any other person.


  • An investment with IBT may contain significant risks and is intended only for sophisticated investors who meet certain eligibility criteria.


  • The material on this website is intended to be viewed only by persons resident in the EEA.


  • The information on this website is not an offer to sell or a solicitation of an offer and does not constitute investment advice.


  • No representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information or opinions contained therein.


  • The information on this website may constitute financial promotion for the purposes of the Financial Services and Markets Act 2000 (“FSMA”).